Recombinant Human A Disintegrin And Metalloproteinase With Thrombospondin Motifs 7 (ADAMTS7) Protein (His)

Name: Recombinant Human A Disintegrin And Metalloproteinase With Thrombospondin Motifs 7 (ADAMTS7) Protein (His)
Brand: Beta LifeScience
SKU: BLC-04507P
Price: 460.0 USD
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: Enzymes, Featured enzyme molecules, Protease, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human A Disintegrin And Metalloproteinase With Thrombospondin Motifs 7 (ADAMTS7) Protein (His) is produced by our Yeast expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9UKP4
Target Symbol	ADAMTS7
Synonyms	A disintegrin and metalloprotease with thrombospondin motifs 7 preproprotein; A disintegrin and metalloproteinase with thrombospondin motifs 7; A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 7; A disintegrin like and metalloprotease with thrombospondin type 1 motif 7; ADAM metallopeptidase with thrombospondin type 1 motif 7; ADAM metallopeptidase with thrombospondin type 1 motif 7 preproprotein; ADAM TS 7; ADAM TS7; ADAM-TS 7; ADAM-TS7; ADAMTS 7; ADAMTS-7; Adamts7; ATS7_HUMAN; COMPase; DKFZp434H204
Species	Homo sapiens (Human)
Expression System	Yeast
Tag	N-6His
Target Protein Sequence	KWVETLVVADAKMVEYHGQPQVESYVLTIMNMVAGLFHDPSIGNPIHITIVRLVLLEDEEEDLKITHHADNTLKSFCKWQKSINMKGDAHPLHHDTAILLTRKDLCAAMNRPCETLGLSHVAGMCQPHRSCSINEDTGLPLAFTVAHELGHSFGIQHDGSGNDCEPVGKRPFIMSPQLLYDAAPLTWSRCSRQYITRFLDRGWGLCLDDPPAKDIIDFPSVPPGVLYDVSHQCRLQYGAYSAFCEDMDNVCHTLWCSVGTTCHSKLDAAVDGTRCGENKWCLSGECVPVGFRPEAVDGGWSGWSAWSICSRSCGMGVQSAERQCTQPTPKYKGRYCVGERKRFRLCNLQACP
Expression Range	242-593aa
Protein Length	Partial
Mol. Weight	41.1kDa
Research Area	Cell Biology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Metalloprotease that may play a role in the degradation of COMP.
Subcellular Location	Secreted, extracellular space, extracellular matrix.
Database References	HGNC: 223 OMIM: 605009 KEGG: hsa:11173 STRING: 9606.ENSP00000373472 UniGene: Hs.16441
Tissue Specificity	Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Detected in meniscus, bone, tendon, cartilage, synovium, fat and ligaments.

Gene Functions References

data show that ADAMTS-7 is associated with a vulnerable plaque phenotype in human carotid lesions. These data support previous observations of a potential proatherogenic role of ADAMTS-7. PMID: 28623250
Multivariate analysis showed that DeltaADAMTS-7(day 7 minus day 1) was independently associated with left ventricular reverse remodeling PMID: 29523183
Genetic variation at the ADAMTS7 locus is associated with reduced severity of coronary artery disease. PMID: 29089340
Studied gene expression of genetic variants of ADAMTS7 in atherosclerotic occlusive peripheral arterial disease (PAD). Found mRNA levels of ADAMTS7 to be significantly higher in PAD patients than controls, and that the rs1994016 CC and rs3825807 TT genotypes may upregulate ADAMTS7 mRNA levels and may influence PAD development. PMID: 28205274
The findings suggest that upregulation of ADAMTS-7 and down regulation of COMP are associated with human AA. PMID: 28849199
The native overfunctional ADAMTS7 allele (A) may accelerate VSMC migration and lead to neointimal thickening, atherosclerosis progression and acute plaque events. PMID: 27614204
miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. PMID: 26816250
Allelic variation that associates with reduced ADAMTS7 expression confers stronger coronary heart disease protection in never-smokers than in ever-smokers. PMID: 28461624
During inflammatory conditions, AP-1 and Sp1 sustained the expression of ADAMTS7, and ADAMTS7 sustained the expression of catabolic genes in nucleus pulposus cells PMID: 27516213
ADAMTS7 and LPA single nucleotide polymorphisms are related to a 24-h ambulatory systolic-diastolic pressure regression index. PMID: 28092973
Expression of miR-26a and miR-29a was significantly down regulated in leukoplakia and cancer tissues but up regulated in lichen planus tissues. Expression of target genes such as, ADAMTS7, ATP1B1, COL4A2, CPEB3, CDK6, DNMT3a and PI3KR1 was significantly down regulated in at least two of three disease types with respect to normal tissues. PMID: 27515006
Our results indicate the presence of ADAMTS-7 in human NP cells and imply its potential role in disc degeneration. PMID: 26446668
The main contribution of this study is the proposal of a pharmacophore for ADAMTS7. PMID: 26872430
The significant associations observed between this coding variant in ADAMTS7 and the risk of CAD development. PMID: 26189211
Logistic regression analysis indicated that the association between ADAMTS-7 and heart failure after AMI was independent from traditional cardiovascular risk factors and other biomarkers PMID: 25885961
Data conclude that ADAMTS-7 level appears to be positively associated with expression of TNF-alpha and Phospho-NF-kappaB P65 in cartilage, which may imply its association with cartilage destruction of ONFH. PMID: 25653475
ADAMTS7 localized to cells having smooth muscle cell markers in human coronary artery disease lesions. Cultured vascular smooth muscle cells had ADAMTS7 at the cytoplasm and cell membrane, where it colocalized with markers of podosomes. PMID: 25712206
There was a reduction in the amount of cleaved ADAMTS7 prodomain in media conditioned by VSMCs of the G/G genotype. PMID: 23415669
statistically significant increase in mRNA expression of ADAMTS-7 and ADAMTS-12 was observed in the endplate cells in degenerative discs compared with nondegenerative discs PMID: 22247065
identified ADAMTS7 as novel locus for CAD and association of ABO with MI in the presence of CAD PMID: 21239051
ADAMTS-7 is the first metalloproteinase found to bind directly to and degrade COMP PMID: 16585064
ADAMTS-7 and ADAMTS-12 are newly identified enzymes responsible for cartilage oligomeric matrix protein degradation in arthritis. PMID: 19098927
Findings demonstrate that ADAMTS-7, a direct target of PTHrP signaling, negatively regulates endochondral bone formation by associating with and inactivating GEP chondrogenic growth factor. PMID: 19487464

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.